Benznidazole
Active ingredient: Benznidazole
In short: Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi. This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) a
What is Benznidazole used for?
Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by
Trypanosoma cruzi.
This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of
T. cruzi
. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Benznidazole dosage
Benznidazole Tablets (12.5 mg and 100 mg) are for oral use and may be taken with or without food
.
Benznidazole Tablets are dosed by body weight (kg)
.
Benznidazole Tablets 100 mg are functionally scored tablets which can be split into one-half (50 mg) or one-quarter (25 mg) at the scored lines to provide doses less than 100 mg
.
Benznidazole Tablets 12.5 mg and 100 mg can be made into slurry as an alternative method of administration
.
The total daily dose for pediatric patients 2 to 12 years of age is 5 mg/kg to 8 mg/kg orally administered in two divided doses separated by approximately 12 hours, for a duration of 60 days .
Body Weight Range (kg) | Dose (mg) | Number of Benznidazole Tablets
12.5 mg | Number of Benznidazole Tablets
100mg | Duration and Frequency of Therapy
Less than 15 kg | 50 mg | 4 tablets | ½ tablet | Administered twice daily approximately 12 hours apart for 60 days.
15 kg to less than 20 kg | 62.5 mg | 5 tablets
20 kg to less than 30 kg | 75 mg | 6 tablets | ¾ tablet
30 kg to less than 40 kg | 100 mg | 1 tablet
40 kg to less than 60 kg | 150 mg | 1 ½ tablets
Greater than or equal to 60 kg | 200 mg | 2 tablets
Obtain a pregnancy test in females of reproductive potential prior to therapy with Benznidazole Tablets
.
A. Preparation of Slurry Using Benznidazole Tablets 12.5 mg for the Pediatric Population with Body Weight Less Than 30 kg
Benznidazole Tablets 12.5 mg may be made into slurry in a specified volume of water for the pediatric population with body weight less than 30 kg . The 12.5 mg tablet slurry is prepared by the following method:
Place the prescribed dose of Benznidazole Tablets 12.5 mg into a cup.
Add the specified volume of water per number of 12.5 mg tablets as shown below.
Body Weight Range (kg) | Dose
(mg) | Number of Benznidazole Tablets 12.5 mg | Quantity of Water for Preparing the Slurry
Less than 15 kg | 50 mg | 4 tablets | 40 mL
15 kg to less than 20 kg | 62.5 mg | 5 tablets | 50 mL
20 kg to less than 30 kg | 75 mg | 6 tablets | 60 mL
Allow the tablets to disintegrate in the cup over a period of approximately 1-2 minutes.
Shake the contents of the cup gently to mix.
Drink the contents of the cup (slurry of tablets with water) immediately.
Rinse the cup with an additional
10 mL of water and drink the whole amount.
B. Preparation of Slurry Using Benznidazole Tablets 100 mg for the Pediatric Population with Body Weight (30 kg or greater)
Benznidazole Tablets 100 mg may be made into a slurry in a specified volume of water for the pediatric population with body weight of 30 kg or greater . The 100 mg tablet slurry is prepared as follows:
Place the prescribed dose of Benznidazole Tablets 100 mg tablets into a cup.
Add the specified volume of water per number of 100 mg tablets as shown below. …
How to take Benznidazole — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (
Instructions for Use).
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential that exposure to Benznidazole Tablets during pregnancy can result in fetal harm.
Advise females to inform their healthcare provider of a known or suspected pregnancy
.
Advise females of reproductive potential to use effective contraception while taking
Benznidazole Tablets and for 5 days after the last dose
.
Lactation
Advise women not to breastfeed during treatment with Benznidazole Tablets
.
Infertility
Advise males of reproductive potential that Benznidazole Tablets may impair fertility
.
Important Administration Instructions
Advise patients and parents/caregivers of pediatric patients taking Benznidazole Tablets that:
•Benznidazole Tablets 100 mg are functionally scored tablets which can be split into one-half (50 mg) or one-quarter (25 mg) at the scored lines to provide doses less than 100 mg.
•Benznidazole Tablets 12.5 mg and 100 mg (whole or split) can be made into a slurry in a specified volume of water for the pediatric population
. …
Warnings & precautions
Do not take this medicine if: Benznidazole Tablets are contraindicated in patients with a history of hypersensitivity reaction to benznidazole or other nitroimidazole derivatives. Reactions have included severe skin and soft tissue reactions
.
Benznidazole Tablets are contraindicated in patients who have taken disulfiram within the last two weeks. Psychotic reactions may occur in patients who are using benznidazole and disulfiram concurrently
.
Benznidazole Tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to benznidazole in patients with Cockayne syndrome
.
Genotoxicity
Genotoxicity of benznidazole has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents
.
A study evaluating the cytogenetic effect of benznidazole in pediatric patients ranging from 11 months to 11 years of age (the safety and effectiveness of Benznidazole Tablets in patients less than 2 years old has not been established) with Chagas disease demonstrated a two-fold increase in chromosomal aberrations. In pediatric patients with Chagas disease who were treated with benznidazole, the median incidence of micronucleated interphase lymphocytes in 20 patients increased 2-fold compared to pre-dose values. In the same study, the mean incidence of chromosomal aberrations in 10 patients also increased 2-fold compared to pre-dose values.
Carcinogenicity
Carcinogenicity has been observed in mice and rats treated chronically with nitroimidazole agents which are structurally similar to benznidazole. Similar data have not been reported for benznidazole
. It is not known whether benznidazole is associated with carcinogenicity in humans. …
Benznidazole side effects
The following serious and otherwise important adverse reactions are discussed in greater detail in other sections of labeling:
Potential for Genotoxicity, Carcinogenicity, and Mutagenicity
Hypersensitivity Skin Reactions
Central and Peripheral Nervous System Effects
Hematological Manifestations of Bone Marrow Depression
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Benznidazole was evaluated in two randomized, double-blind, placebo-controlled trials (Trial 1
1 and Trial 2
2) and one uncontrolled trial (Trial 3
3).
Trial 1 was conducted in pediatric patients 6 to 12 years of age with chronic indeterminate Chagas disease in Argentina. The chronic indeterminate form includes patients with serologic evidence of
T. cruzi infection without symptoms of cardiac or gastrointestinal disease. A total of 106 patients were randomized to receive either benznidazole (5 mg/kg/day twice daily for 60 days; N= 55) or placebo (N=51) and followed for 4 years.
Trial 2 was conducted in pediatric patients 7 to 12 years of age with chronic indeterminate Chagas disease in Brazil. A total of 129 patients were randomized to receive either benznidazole (7.5 mg/kg/day twice daily for 60 days; N = 64) or placebo (N = 65) and followed for 3 years. …
Drug interactions
Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks
.
In
vitro studies showed that benznidazole, at concentrations from 0.03 μM to 100 μM, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.
About this medicine
Benznidazole Tablets contain benznidazole, a nitroimidazole antimicrobial. The chemical name of benznidazole is N-benzyl-2-(2-nitro-1H-imidazol-1-yl) acetamide. The empirical formula is C
12H
12N
4O
3 and the molecular weight is 260.246 g/mol. The structural formula is:
Figure 1: Benznidazole Structure
Benznidazole is a yellowish, practically crystalline powder that is practically insoluble in water, sparingly soluble in acetone and ethanol, and slightly soluble in methanol.
Benznidazole Tablets are white round tablets each containing 12.5 mg or 100 mg of benznidazole, for oral use. The 100 mg white tablets are round and functionally scored twice as a cross on both sides debossed with “E” on one side of each quarter portion. The 12.5 mg white tablets are round and unscored debossed with “E” on one side.
The inactive ingredients are as follows: magnesium stearate, NF; microcrystalline cellulose, NF; monohydrate lactose, NF; pre-gelatinized corn starch, NF; and sodium croscarmellose, NF.
How it works: Benznidazole is a nitroimidazole antimicrobial drug . …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8983d6a0-f63f-4f8e-bba4-38223f39e29b. Read the full official label on DailyMed.